Cyp1a2 and Cyp1b1 can be considered possible therapeutic targets for novel treatments of AMD; it is plausible that these enzymes are targets of SkQ1 when it is administered systemically. This evidence concerns the gene CYP1B1 and age-related macular degeneration.